



Colorado BioScience ASSOCIATION



FOCUS

Letter from the President



Thank you to everyone who sponsored and participated in the BioBogey Golf Tournament last week, especially Colorado Science and Technology Park at Fitzsimons for their lead sponsorship. We enjoyed great weather, golf and networking!

This past Legislative Session we saw many successes for the bioscience industry. CBSA was fortunate to have passed/supported four financing bills thru the 2010-2011, the only economic development bills passed this session. In essence we have extended our BDEGP program to 2018 and increased our grant funds by an additional estimated \$26 million thru 2018 for a total grant program of \$56 million.

We a special thanks to our Legislature for the passage of these initiatives, especially, bill sponsors **Senator Rollie Heath** for SB 047; **Representative Cheri Gerou** for SB 047 and HB 1283; **Representative Jim Riesberg** for SB 047 and HB 1283; and **Senator Pat Steadman** for HB 1283.

The following four bills were passed this session:

- **SB 159: Distribution of State Share of Limited Gaming Revenue (CBSA supported)** - HB1001's BDEGP program receives its funding from gaming and we were able to retain our funding at a slight decrease to \$5.25 million per year.
- **HB 1283: Extending the Bioscience Discovery Evaluation Grant Program (HB 08-1001) CBSA bill** - Extends the sunset date of the program from 2013 to 2018.

- **SB47: Innovation Reinvestment Act (CBSA /CCIA bill)** - Provides additional funding for the BDEGP program. It takes the net increase in State Corporate Income Tax Withholdings within the Bioscience and Clean Tech industry sectors and splits it out 50% to the General Fund, 25% to Bioscience and 25% to CleanTech. Bioscience's 25% will go to the BDEGP program which is estimated at approximately \$2 million of additional monies per year. This will go into effect in 2014.

- **HB 1045: Innovation Investment Tax Credit (CSIA bill, CBSA supported)** - Provides up to \$20,000 for individual angel investors that invest in a minimum of \$25,000 per company. We are currently identifying funding for the program.

On the Federal side, CBSA has been hard at work, holding monthly calls, writing letters and holding face-to-face meetings with our Congressional Delegation to discuss important issues critical to our industry, including, Health Care Reform, Patent Reform, SBIR Reauthorization, FDA reform, IPAB and User fee legislation. If you would like to be involved with our federal and or state policy initiatives, please contact us.

On a personal note, I recently got married and have changed my name to Holli Riebel. Please contact me at my new email hriebel@cobioscience.com.

Enjoy your summer!

Holli Riebel

President and CEO
Colorado BioScience Association

JUNE
2011

Inside this issue:

- 1 From the President
- 2 Company Spotlight
- 3 BioBogey Thank You
- 4 Upcoming Events

www.CoBioScience.com

Company Spotlight: AlloSource

Local Company Pioneers Stem Cell Use From the Gift of Tissue Donation



www.allosource.org

AlloSource, a Colorado Bioscience member since 2002 that is headquartered in Centennial, is renowned for its unwavering focus on its mission of maximizing the gift of human tissue donation by creating innovative life-enhancing and saving tissue products from even the most novel processes.


AlloSource has recently launched the first of its kind stem cell product called AlloStem® Stem Cell Bone Growth Substitute. AlloStem is made from adipose-derived mesenchymal stem cells combined with partially demineralized cancellous bone. As seen in laboratory testing, mesenchymal stem cells exhibit the capacity to differentiate into osteoblast-like (bone building) cells, and the company's further research has indicated that cancellous bone may help to direct the differentiation of these mesenchymal stem cells into osteoblasts. AlloSource hopes that its technology may eliminate the need for people to provide their own bone donations (autograft) for surgical procedures, which could result in less donor site pain and fewer infec-

tions. AlloStem is showing positive clinical results when used in spinal surgery, and the company has initiated several post-market clinical trials in spine, foot, and ankle surgical procedures. AlloSource also produces for NuVasive®, Inc. Osteocel® Plus, which is an allograft cellular bone matrix containing viable mesenchymal stem cells, and is pioneering the use of human amnion as a wound cover with the introduction of AlloWrap™ Natural Wound Cover. Currently, AlloSource is the largest provider of living stem cell transplants in the world.

AlloSource's business model is committed to continuous quality. "We are focused on expanding our leadership position in live cellular allograft production and transplantation based on the success of our current stem cell products," said Tom Cycyota, AlloSource President and CEO. Successful development of novel stem cell therapies, like those being developed by AlloSource, could greatly improve the quality of life for millions of patients living with various chronic and acute medical conditions.

Photo to right:

After being told her leg would need to be amputated following a car accident, Susan Cossabone received AlloStem as a bone void filler and her doctor saw new bone growth in four months.



AlloStem® Stem Cell Bone Growth Substitute



Above: Susan putting on her shoe for the first time following her surgery

Thank You BioBogey Participants and Sponsors!



Registration



CID4 Team



Johnson & Johnson Team



Ernst & Young Team

Upcoming Events

Science Series: Infectious Disease

July 14

7:30am-10:30am

Scientific Education and Research Institute (SERI) Conference Room 9005 Grant Street #100 Thornton, CO 80221
Free for CBSA Members, \$50 Non-Members

Breakfast Keynote: Center for Disease Control and Prevention: Lyle Petersen, Director. Division of Vector-Borne Infectious Disease

Panel Discussion: How Colorado Bio Companies are Impacting Personalized Medicine

Moderator: Kiki Traylor, Amgen

Dan Stinchcomb, Inviragen

Mark Spiecker, Sharklet

David DeLong, BioAMPS

BioBreakfast: Child Health Research

July 27

7:30am-9:00am

Fitzsimons Village, 13100 E Colfax Ave, Aurora, CO 80011 - Building 100 - 3rd Floor

Free for CBSA Members, \$50 Non-Members

Presenter: Dr. Fred Suchy - Chief Research Officer, The Children's Hospital

Oktoberfest

September 1

5:30-8:00pm

Colorado Governor's Residence at the Boettcher Mansion

400 East 8th Avenue, Denver

In partnership with Colorado Cleantech Industry Association

To register, please log into our database system at <https://netforum.avectra.com/eweb/StartPage.aspx?Site=CBSA>.

CBSA Staff

Holli Riebel

President and CEO

hriebel@cobioscience.com

April Giles

Executive Vice President

agiles@cobioscience.com

Tracey Nilson

Program Manager

tnilson@cobioscience.com

Mae Desaire

Director of Marketing

mdesaire@cobioscience.com

Steve Ambriz

Operations Manager

sambriz@cobioscience.com

Find us on Facebook 

www.facebook.com/ColoradoBioScienceAssociation

Follow us on Twitter 

www.twitter.com/cobioscience

Join our group on  **LinkedIn**

<http://tinyurl.com/CBSALinkedInGroup>



<http://coloradobio.blogspot.com/>



www.youtube.com/cobioscience